Quantcast

Corgenix to Exhibit AspirinWorks(R) Test, Discuss New CHARISMA Trial Results at AHA 2008 Meeting

November 5, 2008

DENVER, Nov. 5 /PRNewswire-FirstCall/ — Corgenix Medical Corporation (BULLETIN BOARD: CONX) , a worldwide developer and marketer of diagnostic test kits, has announced it will be exhibiting its AspirinWorks(R) Test November 9 – 11 in booth No. 2536 at the American Heart Association Scientific Sessions 2008 in New Orleans, La.

New CHARISMA trial findings recently published in the American Heart Association’s peer-reviewed medical journal Circulation confirm that elevated urinary levels of the biomarker 11-dehydro thromboxane B2 (11dhTxB2) indicate an increased risk of heart attack, stroke and cardiac death.

The AspirinWorks Test by Corgenix is the only FDA-cleared test that measures urinary 11dhTxB2 to accurately determine the effect of aspirin in apparently healthy individuals. 11dhTxB2 is a metabolite of thromboxane A2, the target of aspirin therapy.

“The American Heart Association conference is an ideal forum in which to discuss the findings on the relationship between elevated 11dhTxB2 levels and cardiovascular risk from the powerful and respected CHARISMA trial,” said Gordon Ens, clinical director of Corgenix Medical Corporation. “This well-designed, prospective outcome study demonstrates the potential value of the AspirinWorks Test for optimizing an individual’s aspirin therapy.”

CHARISMA is a multinational, multicenter, randomized, parallel group, double-blind trial involving 15,603 patients with either clinically established cardiovascular disease or multiple risk factors. The CHARISMA sub-study involved a total of 3,261 aspirin-treated patients from 224 sites in 12 countries.

The AspirinWorks Test was launched in the U.S. in June 2007 following FDA 510(k) clearance, and it is now available nationwide through major medical laboratories as well as direct to consumers through HealthCheckUSA (http://www.healthcheckusa.com/). The test targets a potential U.S. market of over 60 million individuals and a potential global market exceeding 200 million individuals who take aspirin for prevention.

Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test only requires a urine sample that can be obtained in any doctor’s office or patient service center, making the test convenient for both physician and patient.

Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or e-mail: info@aspirinworks.com. More information is also available at http://www.aspirinworks.com/.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at http://www.corgenix.com/.

Statements in this press release that are not strictly historical facts are “forward looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Corgenix Medical Corporation

CONTACT: William Critchfield, Senior VP and CFO of Corgenix MedicalCorp., +1-303-453-8903, wcritchfield@corgenix.com; or Media, Dan Snyders, VicePresident and Public Relations Supervisor of Armada Medical Marketing,+1-303-623-1190, ext. 230, Fax, +1-303-623-1191, dan@armadamedical.com, forCorgenix Medical Corporation

Web site: http://www.corgenix.com/http://www.aspirinworks.com/http://www.healthcheckusa.com/




comments powered by Disqus